Chapter 2 Complications of Peripheral Nerve Stimulation
Open Technique, Percutaneous Technique, and Peripheral Nerve Field Stimulation
Introduction
Using PNS:OT, a lead, often a paddle lead, is surgically placed directly adjacent to the target nerve. An example is placement of a paddle lead along the sciatic nerve for a person with neuropathic sciatica. Using PNS:PT, a percutaneous lead is placed through a needle that is usually guided via a nerve stimulator or by ultrasonography. An example is placement of a percutaneous lead through a needle under ultrasound guidance along nerves of the brachial plexus for a painful brachial plexopathy. Using PNfS, which is also called subcutaneous field stimulation, a lead is typically placed through a needle into the subcutaneous tissue in the direct area of pain experienced by the patient, remote to named peripheral nerves. An example is a lead placed in the subcutaneous tissues for axial low back pain in a patient with postlaminectomy syndrome.1
In contemporary times, PNS techniques, which are reversible, cost effective, nonaddictive, and nonpharmacologic, are based on delivery of low-level electric impulses to pain-generating nerves via an implantable system, consisting of a programmable generator connected to electric transmission leads. Over the past decade, they have been used increasingly to treat a wide range of conditions involving pain in peripheral or cranial neural distributions. In particular, they may be an effective treatment for neuropathic pain that is not accessible or effectively treated by spinal cord or spinal nerve root stimulation. Common neural targets amenable to PNS include cranial nerves (e.g., trigeminal peripheral terminal branches), occipital nerves, segmental truncal nerves (e.g., nerve root, intercostal, ilioinguinal, iliohypogastric, genitofemoral), and upper and lower extremity plexus and peripheral nerves (e.g., ulnar, median, radial, lateral femoral cutaneous, sciatic, anterior and posterior tibial nerves).2
Another reason PNS therapies have increased in popularity may be their lower incidence of complications. In spite of reported complications including infection, lead migration, and device failure, the risk of serious problems resulting from PNS or PfNS therapies appears to be relatively low in clinical practice. Although there has been no formal comparison of PNS versus spinal cord stimulation (SCS) complications, when compared with intrathecal drug delivery, electrical neuromodulation techniques rarely impact morbidity or mortality significantly.3
Selected Complications
Perhaps one of the most significant advantages of PNS is its relatively low rate of complications (Table 2-1). Mobbs et al4 mention relatively minor complications in their retrospective study (currently the largest in the literature), which examines the role of the implantable PNS device in the chronic pain patient. In 38 patients who received implanted PNS devices, six stimulators were removed after implantation (15%). Two were removed due to infection, representing a 5% infection rate. One of these patients had hemophilia despite factor VIII cover, and an episode of bleeding that was further complicated by infection, necessitating stimulator removal. Despite a positive result during the trial period, one stimulator was removed after one month because of minimal effect post-implantation. This patient subsequently improved again after his workers’ compensation issues were resolved. One stimulator was removed at 4 years post-implantation since the patient maintained it was no longer needed. Two stimulators in one patient had an initially positive effect, lasting 3 months, followed by a rapid decline in effect. The patient did not wish to have the stimulators re-trialed or re-implanted. A single lead had to be replaced as it was fractured following a fall from a tree. The stimulator continued to function following revision of the lead. During the follow-up period, two battery generators were replaced because of battery failure and a further two generator/lead combinations were repositioned as they were uncomfortable and restricted arm movement. One electrode was relocated during the trial period due to a substantial, uncomfortable motor effect in an adjacent muscle. A further 8 electrodes were resutured during the second operation due to electrode lead migration.
Complication | Reported Rate (If Reported) |
---|---|
Overall revision rate | 27%32 |
Requiring explant | 15%4 |
Procedural | |
Tissue trauma | Theoretical |
Allergic reactions | Case reports,33* 0.8%34 |
Specific anesthesia-related complications | Anecdotal evidence |
Hemorrhage | Theoretical |
Peripheral nerve trauma | 60%4 |
Organ trauma | Theoretical |
Post-Procedural | |
Infection | 5%,4 3%-5%,17 4.5%,18 1%35 |
Seroma | 2.5%36 |
Lead migration | 27%-33%,34,37 2%35 |
Skin erosion | 12.5%,21 7%35 |
Pain at generator site | 0.9%-5.8%38,39* |
Excessive bleeding | Theoretical |
Sepsis | Theoretical, unpublished case report at the Cleveland Clinic |
Battery failure/hardware failure | 1.6%,40* 2%35 |
Lead migration | 33%,27 24%30 |
* Extrapolated from spinal cord stimulation devices.
Before undertaking a PNS procedure, several factors should be considered, according to a review of surgical procedures pertaining to implantable neuromodulation technology.5 These factors include the incidence, severity, and time to resolution of complications, as well as the net impact on the patient given that complications may detract from the beneficial effect of the procedure.
Procedural Complications
Harm caused to tissues during PNS procedures may consist of bleeding, peripheral nerve trauma, and damage to vital structures (e.g., vessels and organs). Because vital internal structures are vulnerable in PNS, the use of high-quality fluoroscopy is indicated; for example, pneumothorax, a potential organ-related complication of PNS device installation in the thoracic region, is best circumvented by high-quality imaging.6 In deeper tissues, damage to vessels can be evaded by using an open rather than percutaneous technique, which may help to prevent blind injury of vasculature, embolism, and other negative sequelae.
The use of PNS therapy was commonly used to treat pain after previous nerve damage as described by Mobbs et al4 in their retrospective study (currently the largest in the literature) of 38 patients implanted with 41 nerve stimulators. The previous nerve damage included blunt and or sharp nerve trauma (in 14 of 38 patients) and inadvertent injection of a nerve (in nine of 38 patients). The incidence of nerve damage from PNS therapy itself is unknown and believed to be rare. To avoid nerve damage, practitioners should maintain excellent knowledge of relevant anatomy and watch for patient neuralgia and radicular pain in the postoperative period. Treatment of suspected nerve injury may include steroid protocol, anticonvulsants, and referral for neurologic consult.